Determination of the Efficacy of Different Medications for Idiopathic Rhinitis, Impact of Different Medications on Biomarkers of Idiopathic Rhinitis, Safety and Tolerance of Different Medications for Idiopathic Rhinitis
Conditions
Brief summary
Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.
Interventions
DRUGBudesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Detailed in arm descriptions
DRUGLevocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)
Detailed in arm descriptions
DRUG0.9% natural saline
Detailed in arm descriptions
Sponsors
Beijing Institute of Otolaryngology
Shanghai Johnson & Johnson Pharmaceuticals, Ltd.
Beijing Tongren Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Not younger than 18 years old * Diagnosed as idiopathic rhinitis * Signed and volunteered for the study
Exclusion criteria
* Comorbid airway diseases including (but not limited to) upper airway infection, chronic rhinosinusitis, nasal polyps * Allergic to the medicines about to study * Having used oral glucocorticoids or antihistamine agents within 30 days of the enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relief of bothersome symptoms | 2 weeks | Determined by change of visual analog scale for symptoms |
Countries
China
Outcome results
None listed